Cellectricon and Censo Biotechnologies Introduce a Joint Technology Access Program
High-quality Human iPSC-based discovery services for CNS and pain research.
January 26, 2017 – Cellectricon AB and Censo Biotechnologies Ltd are announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research. [Read more…]
|